Sign in

You're signed outSign in or to get full access.

GH

GELESIS HOLDINGS, INC. (GLSHQ)·Q3 2022 Earnings Summary

Executive Summary

  • Q3 2022 revenue was $6.65M (+~121% YoY on total revenue; product revenue $6.44M up 114% YoY), but declined sequentially from $8.97M on deliberately lower marketing spend; gross margin expanded to 44% from 8% YoY (47% in Q2) .
  • Net loss improved materially YoY to $(14.1)M from $(30.7)M; Adjusted EBITDA loss improved to $(12.3)M from $(26.2)M YoY, reflecting scale and lower COGS per unit .
  • Management reiterated full-year 2022 guidance (revenue $27–$30M; gross profit $11–$13M; adj. EBITDA $(75)–$(80)M) and announced plans to file for OTC classification of Plenity, targeting potential clearance by mid-2023 (Q1 submission) .
  • Catalysts: OTC pathway (reduced CAC, broader access) and delivery against reiterated FY22 outlook; risks include funding dependence and going-concern language in risk disclosures .

What Went Well and What Went Wrong

  • What Went Well

    • Strong YoY growth: product revenue +114% to $6.44M; units sold +101% to 92,070; new members +50% to 23,500 .
    • Gross margin expansion: 44% vs 8% YoY; gross profit +$2.6M YoY on volume and lower unit costs .
    • Strategic step: “pursuing an application with the FDA to change the classification of Plenity to over-the-counter,” expected submission in the coming months with potential clearance by mid-2023; CEO: “an OTC classification… should improve our cost of acquiring new members… reducing our reliance on the capital markets to reach profitability” .

  • What Went Wrong

    • Sequential revenue decline as marketing spend was reduced in Q3 versus H1, which management noted would impact revenue; total revenue fell to $6.65M from $8.97M in Q2 .
    • Operating losses remain significant: Q3 net loss $(14.1)M; Adjusted EBITDA $(12.3)M; SG&A was $17.0M in Q3 (though down from $32.5M in Q2) .
    • Liquidity/funding dependence: Full-year guidance tied to financing capacity; risk disclosures cite ability to raise financing, going concern, and listing risks among key uncertainties .

Financial Results

Quarterly trend (oldest → newest)

MetricQ3 2021Q1 2022Q2 2022Q3 2022
Total Revenue ($M)$3.014 $7.514 $8.973 $6.652
Product Revenue ($M)$3.014 $7.514 $8.973 $6.443
Licensing Revenue ($M)$0.000 $0.000 $0.000 $0.209
Gross Margin (%)8% 34.6% 47% 44%
Net Loss ($M)$(30.730) $(5.703) $(12.513) $(14.149)
Adjusted EBITDA ($M)$(26.205) $(26.932) $(24.169) $(12.326)
Diluted EPS ($)$(9.61) $(0.70) $(0.17) $(0.20)

YoY and QoQ context (computed from cited values)

  • Total revenue: +~121% YoY ($6.652M vs $3.014M), QoQ −26% ($6.652M vs $8.973M) .
  • Gross margin: +36 pp YoY (44% vs 8%), −3 pp QoQ (44% vs 47%) .
  • Net loss: improved YoY ($(14.1)M vs $(30.7)M), widened QoQ ($(14.1)M vs $(12.5)M) .

Segment/revenue mix (Q3 2022)

Revenue ComponentQ3 2022 ($M)
Product Revenue$6.443
Licensing Revenue$0.209
Total Revenue$6.652

KPIs

KPIQ3 2021Q1 2022Q2 2022Q3 2022
New Members Acquired15,700 40,400 43,800 23,500
Units Sold45,825 114,570 129,890 92,070
ASP per Unit, Net ($)$65.77 $65.58 $69.08 $69.98
Gross Profit ($M)$0.251 $2.601 $4.187 $2.827
Gross Margin (%)8% 34.6% 47% 44%
Product Revenue ($M)$3.014 $7.514 $8.973 $6.443

Additional P&L and balance sheet references (Q3 2022)

  • SG&A $17.032M; R&D $3.365M; Total operating expenses $24.580M .
  • Cash & equivalents $24.847M; Deferred income (current) $28.895M; Notes and convertible notes payable (current) $30.101M .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Product Revenue, NetFY 2022$27–$30M (updated Aug 15, 2022) $27–$30M (reiterated Nov 14, 2022) Maintained
Gross ProfitFY 2022$11–$13M (updated Aug 15, 2022) $11–$13M (reiterated Nov 14, 2022) Maintained
Adjusted EBITDAFY 2022$(75)–$(80)M (updated Aug 15, 2022) $(75)–$(80)M (reiterated Nov 14, 2022) Maintained
Product Revenue, NetFY 2022$58M (initial May 12, 2022) $27–$30M (updated Aug 15) Lowered on Aug 15

Notes: The Aug 15 update cited reduced H2 marketing investment and liquidity considerations; Q3 reiterated the updated ranges .

Earnings Call Themes & Trends

(Transcript not available in our dataset; themes below sourced from Q1–Q3 earnings releases)

TopicPrevious Mentions (Q-2 and Q-1)Current Period (Q3 2022)Trend
Marketing spend/awarenessNational broad awareness campaign launched Jan 31; drove record traffic/requests; strong Q1–Q2 momentum; CAC focus .Reduced marketing spend in Q3 vs H1; acknowledged revenue impact .Shift toward cost discipline; sequential headwind.
Distribution/partnersTelehealth partner Ro placed $15M pre-order in June; total pre-paid Plenity orders $55M .No new pre-order disclosed; licensing revenue of ~$0.21M appears in Q3 .Mix evolving; modest non-product revenue emerges.
Regulatory/OTC—Pursuing OTC classification; submit Q1 2023; potential clearance by mid-2023; expected to reduce CAC and reliance on capital markets .New strategic pivot; potential 2023 catalyst.
Manufacturing/COGS2021 scale-up improved margins; margin gains in Q1–Q2 (34.6% to 47%) .44% GM; still far above 8% LY, on volume and lower unit costs .Sustained structural improvement.
R&D/clinicalGS200 LIGHT-UP study: clinically meaningful responses; additional preclinical microbiome data .New data at Obesity Week: Gel-B boosting Akkermansia; GS200 insulin sensitivity signals .Continued pipeline updates.
Liquidity/financingPrivate placement $25M (July); B. Riley equity facility up to $50M (Aug) .Reiterated FY guide contingent historically on financing; risk disclosures emphasize financing/going concern/listing .Ongoing financing dependence.

Management Commentary

  • CEO (Q3): “We continued to see strong uptake… 114% topline growth… Despite a significant reduction in marketing spend… we acquired over 23,500 new members and sold over 92,000 units… in line with our current guidance” .
  • CEO on OTC plan: “To take advantage of Plenity’s differentiated profile… we are pursuing an application… to over-the-counter… [which] should improve our cost of acquiring new members… thereby reducing our reliance on capital markets… could potentially receive market clearance by the middle of next year” .
  • CFO (Q2 context): Liquidity bolstered via Ro pre-order and $25M promissory notes; B. Riley committed equity financing up to $50M for optional issuance .

Q&A Highlights

  • The company held a conference call on Nov 14, 2022, but a transcript was not available in our dataset; the press release emphasized that reduced marketing spend impacted Q3 revenue and reiterated FY22 guidance, while highlighting the forthcoming OTC submission .

Estimates Context

  • S&P Global (Capital IQ) consensus for GLSHQ Q3 2022 revenue and EPS was unavailable in our feed due to missing mapping, so we cannot assess beat/miss versus Street. Values retrieved from S&P Global were unavailable.
  • Given the lack of published consensus in our dataset, estimate revisions may hinge on: sequential revenue reset from lower marketing, sustained gross margin improvements, and potential OTC implications on 2023 demand funnel .

Key Takeaways for Investors

  • Sequential revenue reset reflects disciplined marketing spend, but YoY growth and margin expansion remain strong, suggesting improved unit economics at scale .
  • The OTC pathway is the primary strategic catalyst for 2023: it could expand access, lower CAC, open new channels, and reduce capital intensity if cleared mid-2023 .
  • FY22 guidance was reiterated despite a softer Q3, implying confidence in Q4 execution and/or continued mix/COGS benefits; monitor delivery against the $27–$30M revenue and $11–$13M GP ranges .
  • Cash stood at $24.85M as of Sep 30, 2022; funding flexibility (and timing) remains critical given ongoing operating losses and management’s explicit financing and going-concern risk disclosures .
  • KPI trends show healthy ASP and improved gross margin, but new member adds and units slowed with lower spend; investor focus will be on the elasticity between marketing intensity and revenue .
  • Watch for licensing or other non-core revenue contributions (first appearance in Q3) and any updates on partner dynamics (e.g., Ro) as potential incremental supports to cash flow .
  • Near-term trading setup: headlines on OTC filing/clearance timing, Q4 revenue cadence versus reiterated guide, and any financing developments are likely to drive the stock narrative .